Business Context and Reporting Period
Company: Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.)
Filing Date: February 17, 2025 (Report Date)
Event: Consummation of Business Combination and Domestication
On February 17, 2025, the Company completed a business combination with Aspire Biopharma, Inc. The transaction involved the domestication of the Company from the Cayman Islands to Delaware and the merger of Aspire Biopharma into a wholly-owned subsidiary. The Company changed its name from "PowerUp Acquisition Corp." to "Aspire Biopharma Holdings, Inc." and ceased being a shell company. Following the closing, the Company had 46,007,513 shares of common stock and 14,375,000 public warrants outstanding.
Key Financial Metrics and Capital Structure
Debt Financing (Securities Purchase Agreement):
- Principal Amount: $3,750,000 in senior secured convertible debentures.
- Purchase Price: $3,000,000 (reflecting a 20% original issue discount).
- Conversion Terms: Convertible at 92.5% of the lowest daily VWAP over a five-day period, subject to a floor price of $4.00 per share.
- Security: Secured by a security interest in all Company assets and guaranteed by Aspire Biopharma, Inc.
- Default Provisions: Interest rate increases to 2% per annum and acceleration of 125% of principal and accrued interest upon default.
- Principal Amount: Up to $500,000 (20% OID).
- Interest Rate: 10% per annum.
- Exit Fee: 10% of principal and accrued interest.
- Maturity: June 1, 2025, or upon raising $5,000,000 in gross proceeds.
- SPA Commitment Shares: 2,106,527 shares issued to debenture investors (1,000,000 freely tradable subject to leak-out).
- Blackstone Commitment Shares: 1,795,000 shares issued to Blackstone Capital Advisors.
The filing does not provide specific cash balance or operating cash flow figures for the combined entity. Liquidity is supported by the $3,000,000 net proceeds from the debenture offering and the availability of the Blackstone working capital facility.
Material Changes Versus Prior Period
- Corporate Status: Transitioned from a Cayman Islands shell company (PowerUp Acquisition Corp.) to a Delaware operating corporation (Aspire Biopharma Holdings, Inc.).
- Capital Structure: Significant increase in debt obligations ($3.75M debentures + up to $0.5M Blackstone note) and equity dilution via commitment shares.
- Accounting Firm: Dismissed Marcum LLP (effective Feb 17, 2025) due to a material weakness in internal controls over debt discount and amortization identified in the prior Form 10-Q. Engaged Bush & Associates CPA LLC (effective Feb 20, 2025).
- Ownership: Pre-closing stockholders of PowerUp hold approximately 76.1% of the outstanding shares immediately following the closing.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook:
The Company intends to retain all earnings for business operations and does not anticipate declaring cash dividends in the foreseeable future. The Company expects to file a registration statement within 40 days of the SPA closing to register the debenture-related securities.
Risks and Contingencies:
- Going Concern: The prior auditor (Marcum LLP) included an explanatory paragraph regarding the Company's ability to continue as a going concern.
- Internal Controls: A material weakness in internal controls over financial reporting (specifically debt discount and amortization) was previously identified.
- Debt Covenants: The new debentures prohibit incurring new indebtedness not subordinated to the investors until the debentures are paid in full.
- Market Risks: Risks include maintaining Nasdaq listing, realizing anticipated benefits of the combination, and the ability to raise future financing.
Unusual Items:
- Related Party Transactions: The debenture investors include Cobra Alternative Capital Strategies, LLC, controlled by Lance Friedman (former Director of Investor Relations). Blackstone Capital Advisors, Inc., also controlled by Friedman, provided the working capital loan.
- Leak-Out Agreement: Investors in the debenture offering are subject to a leak-out agreement limiting sales to 15% of daily trading volume.
Investor Verification Checklist
- Debt Service Obligations: Verify the impact of the 20% OID and 10% exit fee on future cash burn and dilution upon conversion.
- Internal Control Remediation: Confirm the status of remediation for the material weakness in debt accounting identified by the former auditor.
- Related Party Conflicts: Review the extent of influence held by Lance Friedman through Cobra Alternative Capital Strategies and Blackstone Capital Advisors.
- Pro Forma Financials: Review Exhibit 99.1 for unaudited pro forma condensed combined financial information to assess the combined entity's financial position.
- Registration Rights: Monitor the filing of the registration statement required within 40 days of the SPA closing to ensure liquidity for the commitment shares.